Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

356
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
356
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

1.6K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.6K
Neural Regulation01:37

Neural Regulation

39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early complications within 30 days after radical cystectomy: The top seven complications and their predictors.

Investigative and clinical urology·2026
Same author

Challenges in umbilical pathology: far beyond the obvious-a case report.

AME case reports·2026
Same author

First identification and molecular characterization of CTX-M-15 extended-spectrum β-lactamase and OXA-9 β-lactamase in <i>Haemophilus influenzae</i> in the Iberian Peninsula.

Antimicrobial agents and chemotherapy·2026
Same author

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis.

Cancer treatment and research communications·2026
Same author

Spontaneous Bladder Rupture during Vaginal Delivery.

Case reports in urology·2026
Same author

Intravascular Lithotripsy For Severe Peripheral Artery Calcification - A 3-Year Single Centre Experience.

Portuguese journal of cardiac thoracic and vascular surgery·2025

Related Experiment Video

Updated: Jul 27, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K

Levodopa-Induced Pseudopheochromocytoma.

Joana Cardoso1, Ana Silveira1, Sara Duarte1

  • 1Hospital da Horta, Azores, Portugal.

European Journal of Case Reports in Internal Medicine
|June 12, 2023
PubMed
Summary

Pseudopheochromocytoma, a condition mimicking pheochromocytoma, can be caused by levodopa. This case highlights levodopa-induced pseudopheochromocytoma, emphasizing drug-induced hypertension management.

Keywords:
Parkinson’s diseasePseudopheochromocytomalevodopaparoxysmal hypertension

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.0K

Related Experiment Videos

Last Updated: Jul 27, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.0K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Nephrology

Background:

  • Pseudopheochromocytoma presents with symptoms similar to pheochromocytoma, including paroxysmal hypertension.
  • Key diagnostic features include normal or moderately elevated catecholamine and metanephrine levels without a tumorous cause.
  • Exclusion of pheochromocytoma through imaging and scintigraphy is crucial.

Purpose of the Study:

  • To describe a case of pseudopheochromocytoma linked to levodopa therapy.
  • To illustrate the clinical and laboratory presentation of levodopa-induced pseudopheochromocytoma.
  • To highlight the importance of considering medication side effects in hypertensive patients.

Main Methods:

  • Case report of a patient with paroxysmal hypertension, headache, sweating, and palpitations.
  • Laboratory analysis revealed increased plasma and urinary metanephrine levels.
  • Diagnostic workup excluded adrenal or extra-adrenal tumors, including I-123 MIBG scintigraphy.

Main Results:

  • The patient's symptoms began after initiating levodopa treatment.
  • No evidence of a tumorous cause for the hypertension was found.
  • Symptoms resolved completely after discontinuing levodopa.

Conclusions:

  • Pseudopheochromocytoma and pheochromocytoma share clinical and laboratorial similarities but have distinct etiologies.
  • Diagnosis relies on paroxysmal hypertension with abnormal catecholamine/metanephrine levels post-tumor exclusion.
  • Levodopa is a potential cause of pseudopheochromocytoma, especially when combined with other drugs affecting catecholamine metabolism.